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Recent advances in genetics and neuropathology support the idea that amyotrophic lateral sclerosis (ALS)
and frontotemporal lobar dementia (FTD) are two ends of a disease spectrum. Although several animalKeywords:
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models have been developed to investigate the pathogenesis and disease progression in ALS and FTD,
there are signiﬁcant limitations that hamper our ability to connect these models with the neurode-
generative processes in human diseases. With the technical breakthrough in reprogramming biology, it is
now possible to generate patient-speciﬁc induced pluripotent stem cells (iPSCs) and disease-relevant
neuron subtypes. This review provides a comprehensive summary of studies that use iPSC-derived
neurons to model ALS and FTD. We discuss the unique capabilities of iPSC-derived neurons that capture
some key features of ALS and FTD, and underscore their potential roles in drug discovery. There are,
however, several critical caveats that require improvements before iPSC-derived neurons can become
highly effective disease models.
This article is part of a Special Issue entitled SI: Exploiting human neurons.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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.J., Modeling ALS and FTD wi1. The expanding landscape of amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD)
1.1. ALS and FTD: two ends of a disease spectrum
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's
disease, is an adult-onset neurodegenerative disease that affects-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
th iPSC-derived neurons. Brain Research (2016), http://dx.doi.org/
S. Lee, E.J. Huang / Brain Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎2upper and lower motor neurons. As initially described by Jean-
Martin Charcot more than 140 years ago, the key clinical features
in ALS patients include muscle wasting, and progressive loss of
spinal motor neurons and upper motor neurons and their axons in
the lateral columns of the spinal cord. This century-old classic
deﬁnition, however, has been under scrutiny due to the emerging
appreciations that some ALS patients who exhibit deﬁcits in
higher cognitive functions at the early stage of their clinical course
eventually develop behavioral variant frontotemporal dementia
(bvFTD). Indeed, it has been estimated that 15% of FTD patients
develop features of ALS (Lomen-Hoerth et al., 2002; Ringholz et al.,
2005), and up to 50% of ALS patients show abnormal neu-
ropsychological testing indicative of frontal lobe dysfunctions
(Lillo et al., 2011; Lomen-Hoerth et al., 2003). Furthermore, pa-
tients with FTD–ALS usually have shortened life span compared to
patients with pure FTD or ALS (Olney et al., 2005). Together, these
studies provide a new framework to re-evaluate the diagnostic
criteria for ALS (Strong et al., 2009), and a new clinical paradigm in
which ALS and FTD are linked within a disease spectrum (Fig. 1).
1.2. Unraveling the genetics and neuropathology of ALS and FTD
The idea that FTD and ALS are a disease spectrum is further
supported by genetic evidence that patients with familial FTD–ALS
and ALS often carry mutations in the same genes (Ling et al., 2013).
In fact, of all the different subtypes of FTD, FTD–ALS cases have
such a high propensity (30%) of familial inheritance that genetic
counseling is now considered as the standard of care for these
patients (Goldman et al., 2005). Among a growing number of
genes implicated in familial ALS and FTD–ALS (Fig. 1), mutations in
three genes account for the majority of cases. These mutations
include missense mutations in genes encoding two RNA/DNA
binding proteins, TDP-43 (TARDBP or TAR-DNA-binding protein-
43) and FUS/TLS (fused in sarcoma/translocation in liposarcoma or
FUS) and the GGGGCC hexanucleotide expansions in C9ORF72 gene
(Lee et al., 2012; Ling et al., 2013). The discovery of TDP-43 as a
component in the ubiquitin-positive, tau-negative insoluble pro-
tein aggregates in neurons and glia represents a major break-
through in FTD research (Arai et al., 2006; Neumann et al., 2006).
Moreover, the impact of this discovery goes beyond the identiﬁ-
cation of a single disease gene and essentially ushers in a new era
of research that focuses on the potential contributions of tran-
scription, RNA splicing and RNA metabolism on neurodegenerative
diseases.Fig. 1. A schematic diagram illustrating the disease spectrum, genetics and proteinopath
manifestations indicate that ALS and FTD are two ends of a disease spectrum. It is estim
impairments in frontal executive functions. This new clinical paradigm is further sup
mutations, in particular mutations that involve the GGGGCC hexanucleotide expansion
TDP-43 and FUS. FTD–ALS and ALS patients with mutations in the same gene (C9ORF
containing distinct protein aggregates of TDP-43 or FUS proteins. Therefore, the neuropa
FTLD (frontotemporal lobar degeneration)-tau (FTLD-tau), FTLD-TDP, FTLD-FUS, ALS-TDP
Please cite this article as: Lee, S., Huang, E.J., Modeling ALS and FTD wi
10.1016/j.brainres.2015.10.003iTDP-43 is originally identiﬁed to bind to the TAR DNA sequence
in HIV-1 genome to regulate viral gene expression (Ou et al., 1995).
Under physiological conditions, TDP-43 is a ubiquitous nuclear
protein. In FTD patients, however, TDP-43 proteins form ag-
gregates that are found predominantly in neuronal cytoplasm and
dystrophic neuronal processes (Arai et al., 2006; Neumann et al.,
2006). This distinctive feature, also known as TDP-43 proteino-
pathy, deﬁnes a major neuropathological diagnosis entity in
frontotemporal lobar degeneration (FTLD-TDP) and in sporadic ALS
(ALS-TDP) (Fig. 1) (Mackenzie et al., 2011, 2010). Several sub-
sequent studies show that dominant mutations in the TARDBP
gene can also be identiﬁed in familial ALS and FTD patients (Lat-
tante et al., 2013). The identiﬁcation of autosomal dominant mu-
tations in the FUS gene in large kindred of familial ALS (FALS)
further expanded the genetic and neuropathological landscape of
ALS (Kwiatkowski et al., 2009; Vance et al., 2009). Similar to TDP-
43, FUS proteins reside primarily in the neuronal nuclei, but in
ALS-FUS patients FUS proteins form large aggregates in the cyto-
plasm. The morphology of FUS proteinopathy in FALS ranges from
diffuse and dense cytoplasmic aggregate present in late onset
cases, to basophilic inclusions commonly found in juvenile FALS
with FUS-P525L mutation. Finally, in 2011 two groups in-
dependently reported the GGGGCC hexanucleotide repeat expan-
sions in the noncoding region of the C9ORF72 gene as causal links
to ALS and FTD (DeJesus-Hernandez et al., 2011; Renton et al.,
2011). Although TDP-43 proteinopathy can be detected in FTLD
and ALS patients with C9ORF72 mutations, the neuropathological
features in these cases are quite heterogeneous and also include
prominent ubiquitin and p62 positive, but TDP-43 negative in-
tracytoplasmic and intranuclear inclusions (Bigio, 2012; Mack-
enzie et al., 2014). Interestingly, TDP-43 proteinopathy has also
been identiﬁed in protein aggregate myopathies, such as inclusion
body myositis (Olive et al., 2009). Together, these results raise the
possibility that TDP-43 proteinopathy may not be speciﬁc for FTLD
or ALS.
It is estimated that mutations in TARDBP and FUS each account
for 5% of FALS, whereas the GGGGCC expansion mutations in
C9ORF72 account for 20–40% of familial ALS and FTD–ALS cases,
depending on the population studied. Given the large number of
cases with C9ORF72 mutations, there have been tremendous in-
terests in understanding the underlying mechanisms. While sev-
eral mechanisms, including RNA toxicity and dipeptide accumu-
lation (Ash et al., 2013; Donnelly et al., 2013; Mori et al., 2013),
have been proposed for C9ORF72 mutations, the rapidlyy of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Clinical
ated that 15% of FTD patients develop ALS and up to 50% of ALS patients show
ported by the ﬁndings that patients with FTD–ALS and ALS share similar genetic
in the non-coding region of the C9ORF72 gene and two RNA/DNA binding protein
72, TARDBP or FUS) often exhibit similar neuropathological features with neurons
thology of these patients can be categorized by the nature of the proteinopathy into
, ALS-FUS or ALS-SOD1.
th iPSC-derived neurons. Brain Research (2016), http://dx.doi.org/
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more surprises in the future. One important feature noted in a
recent study indicates that the age of disease onset for FALS caused
by FUS, TARDBP and C9ORF72 mutations differ quite drastically in
that mutations in FUS account for 35% of FALS in patients
younger than 40 years old, whereas mutations in C9ORF72 are
much more common in patients older than 50 years of age
(Millecamps et al., 2012). Indeed, meta-analyses of 154 ALS cases
with FUS mutations (including FALS and SALS with de novo FUS
mutations) show an average disease onset of 43.8717.4 years
(Deng et al., 2014; Lattante et al., 2013). More than 60% of cases
with FUS mutations show disease onset before 45 years of age,
with many juvenile ALS cases presenting with disease onset in late
teens and early 20's (Baumer et al., 2010; Huang et al., 2010). These
ﬁndings are similar to those from another study using smaller
sample size, and show that the average disease onset for FUS, SOD1
or TARDBP mutations is 43.6715.8, 47.7713.0 and 54.7715.3,
respectively (Yan et al., 2010). Kaplan–Meier survival analysis
shows statistically signiﬁcant differences in the trend of age of
onset among these three genes. This distinctive feature of FUS
mutations raises the intriguing hypothesis that, despite the simi-
larities between TDP-43 and FUS proteins, mutations in FUS may
target divergent mechanisms that perturb the development and
maintenance of synaptic homeostasis in the nervous system in
early postnatal life and during the aging process (Qiu et al., 2014;
Sephton et al., 2014).Fig. 2. A schematic diagram illustrating the generation of disease-speciﬁc induced
pluripotent stem cells (iPSCs) and its applications in modeling disease phenotypes
and in identifying therapeutic targets.2. Induced pluripotent stem cells (iPSCs) as models for ALS
Recent advances in stem cell biology have provided exciting
and unprecedented opportunities to develop disease-speciﬁc cell
types that allow us to understand and explore mechanisms that
contribute to pathogenesis of disease. In particular, the ability to
reprogram somatic cells into induced pluripotent stem cells
(iPSCs) provide obvious advantages to generate patient-speciﬁc
iPSCs that carry the exact same genetic makeup, including muta-
tions that may contribute to the disease process (Fig. 2) (Takahashi
et al., 2007; Takahashi and Yamanaka, 2006). These iPSCs can be
differentiated into cell types that provide strong correlations to
clinical benchmarks and pathology (Han et al., 2011). In addition,
patient-speciﬁc iPSCs may also serve as powerful resources for
personalized medicine, including drug discovery, genetic testing,
and ultimately cell replacement therapy (Fig. 2). Despite these
unique advantages, one important caveat with the iPSC models is
that a myriad of epigenetic changes due to reprogramming and the
lengthy process of cell selection and in vitro cultures might con-
tribute to the variations in this system. Here we focus on the re-
cent progress on using induced pluripotent stem cell (iPSC)-de-
rived neurons as the new models to investigate disease mechan-
isms for ALS and FTD. The salient features of these studies are
summarized in Table 1.
2.1. Modeling SOD1 mutations
Autosomal dominant mutations in the superoxide dismutase 1
(SOD1) are the ﬁrst to be causally linked to familial ALS. Following
this discovery, several transgenic rodent models overexpressing
SOD1 mutant proteins become widely used to reveal a plethora of
disease mechanisms, including axonal transport defects, oxidative
stress, protein misfolding, mitochondrial dysfunction and ex-
citotoxicity. In addition, non-cell autonomous pathogenic me-
chanisms involving astrocytes, microglia and NG2 cells, have also
been identiﬁed to contribute to neurodegeneration caused by
mutant SOD1 overexpression. The availability of iPSC-derived
motor neurons from patients with SOD1mutations provide uniquePlease cite this article as: Lee, S., Huang, E.J., Modeling ALS and FTD wi
10.1016/j.brainres.2015.10.003iopportunities to capture salient neurodegenerative features of
ALS-SOD1 at more realistic expression levels and to re-evaluate
disease mechanism(s) that may lead to novel therapeutic insights.
By reprogramming skin ﬁbroblasts from two patients with
SOD1A4V mutation (SOD1A4V/þ), Kiskinis et al. (2014) showed that
iPSC-derived ISLþ/HB9þ SOD1A4V/þ motor neurons exhibit a
higher propensity to undergo apoptosis, similar to those observed
in the SOD1G93A mouse model. In addition, iPSC-derived SOD1A4V/þ
motor neurons show signiﬁcant reductions in soma size, and fewer
and shorter neuronal processes. These pathological features ap-
pear to be speciﬁc to motor neurons because ISL- SOD1A4V/þ
neurons in the same culture conditions do not show similar de-
fects. To further demonstrate the speciﬁcity of these phenotypes,
the authors used zinc ﬁnger nuclease (ZFN)-mediated gene tar-
geting to correct the SOD1A4V/þ mutation and showed that motor
neurons with corrected mutation (SOD1þ /þ) show signiﬁcant
rescues in both survival and soma size.
Genome-wide transcriptome analyses in FACS-puriﬁed
SOD1A4V/þ motor neurons using RNA-seq further reveal altered
expression in genes related to cytoskeleton organization. Con-
sistent with these ﬁndings, another study shows that iPSC-derived
motor neurons carrying SOD1D90A mutation progressively develop
neuroﬁlament (NF) inclusions such that by Day 31 in cultures
460% of SOD1D90A motor neuron cell body and 25% of neurites
contain NF inclusions (Chen et al., 2014). The development of NF
inclusions in SOD1D90A motor neurons correlates with degenera-
tion of neurites. The underlying mechanism for the formation of
NF inclusion in SOD1D90A motor neurons appears to be caused by
mutant SOD1 proteins that bind to the 3′UTR of NF-L mRNA, de-
stabilize NF-L mRNA and thereby change the proportion of NF
subunit composition. In addition to the defects in cytoskeletonth iPSC-derived neurons. Brain Research (2016), http://dx.doi.org/
Table 1
Summary of the results from iPSC-derived neurons as disease models for ALS and FTD.
Genetic mutation Neuron types Analyses Phenotypes and mechanisms Gene targeted corrections, drug screening or
other interventions
References
SOD1D90A Motor neurons Cell biology and immune-gold EM  Neuroﬁlament aggregates and inclusions
 Mutant SOD1 binds to 3′UTR of NF-LmRNA and
destabilizes NF-L mRNA
TALEN-mediated homologous recombination Chen et al.
(2014)
SOD1A4V Motor neurons RNA-seq gene expression proﬁling  Increased apoptosis, reduced soma size and
shorter and fewer processes
 Defects in mitochondrial morphology and
motility
 Unfolded protein response (UPR) and ER stress
Zinc ﬁnger nuclease (ZFN) correction of SOD1A4V
mutation improves survival and soma size
Kiskinis et al.
(2014)C9ORF72
SOD1G93A,
SOD1L144F
Motor neurons MN survival assay, Electrophysiology  Improves motor neuron survival via cell-au-
tonomous mechanisms by Inhibition of GSK3α/
β andTak1-MKK4-JNK-c-Jun
Small molecule screening Yang et al.
(2013)
SOD1A4V Motor neurons Extracellular multielectrode array recording
(MEAs) and whole-cell patch clamp
 Hyperexcitability that can be blocked by
Retigabe
n.d. Wainger et al.
(2014)SOD1D90A
SOD1G85S
C9ORF72
FUSM511FS
FUSH517Q
TDP-43M337V Motor neurons and astrocytes Selective cellular vulnerability by longitudinal
ﬂuorescent microscopy
 TDP-43M337V neurons show selective cellular
vulnerability to PI3K inhibitors
 TDP-43M337V neurons show increase in de-
tergent-insoluble TDP-43 proteins
 TDP-43M337V astrocytes show increase in TDP-
43, but no non-cell autonomous cytotoxicity to
iPSC neurons
TDP-43M337V allele-speciﬁc siRNA knock-down
reduces cytosolic TDP-43
Bilican et al.
(2012)
Serio et al.
(2013)
Nishimura et al.
(2014)
TDP-43Q343R Motor neurons Cell biology, gene expression proﬁling and
drug screening
 Reduced NFM and NFL expression
 Increase in detergent-insoluble TDP-43 in ALS
neurons
 Increased TNFα/NFκB signaling pathway and
sensitivity to arsenite-induced cell death
 Gene expression proﬁling reveals increases in
RNA metabolism-related genes in ALS neurons
Candidate drug screenings identify HAT inhibitor
Anacardic acid to decrease TDP-43 mRNA, reduce
insoluble TDP-43 and increase NFM/NFL
expression
Egawa et al.
(2012)TDP-43M337V
TDP-43G298S
TDP-43A90V Tuj1þ neurons Electrophysiology, cellular response to stress
and microRNA expression
 Cytoplasmic localization of TDP-43 in TDP-
43A90V neurons
 Reduced total TDP-43 protein level in TDP-
43A90V neurons
 Decrease in miR-9 and precursor
n.d. Zhang et al.
(2013)TDP-43M337V
TDP-43M337V Motor neurons Axonal transport of RNA beacons, live ima-
ging of RNA transport
 Axonal transport of target mRNAs n.d. Alami et al.
(2014)TDP-43G298S
TDP-43A315T
C9ORF72 Mixed neuron-glia cultures FISH for RNA foci, RAN translation pathology,
identiﬁcation of RNA binding proteins for
GGGGCC RNA and ASO treatment
 RNA foci and RAN translation products
detected
 Screening for RNA binding proteins that bind
GGGGCC and characterize ADARB2
 Gene expression proﬁling
 Increase in glutamate cytotoxicity
ASOs targeting C9ORF72 rescues glutamate cy-
totoxicity and reverses disease-speciﬁc tran-
scriptional changes
Donnelly et al.
(2013)
C9ORF72 Motor neurons Southern blot analyses for GGGGCC expan-
sion, FISH for RNA foci, gene expression pro-
ﬁling and ASO treatment
 RNA foci detected, but not RAN translation
products
 Support gain-of-function properties in RNA
foci to sequester RNA binding proteins and af-
fect splicing and transcription
 Gene expression proﬁling reveals enrichment
in genes related to cell adhesion, synaptic
transmission and neural differentiation
 C9-ALS neurons show reduced excitability
upon depolarization
ASOs targeting C9ORF72 reverses disease-spe-
ciﬁc transcriptional changes
Sareen et al.
(2013)
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rons also reveals defects in mitochondrial function and structure.
In support of these ﬁndings, ultrastructural analyses show distor-
tion of mitochondrial morphology in SOD1A4V/þ motor neurons. In
addition, live cell imaging shows that mitochondrial movement is
reduced in the axons of SOD1A4V/þ neurons (Chen et al., 2014).
Another major group of genes misregulated in SOD1A4V/þ mo-
tor neurons are those related to ER stress and unfolded protein
response (UPR). While the exact cause(s) leading to the activation
of ER stress and the UPR pathways remain unclear, at least two
mechanisms may contribute to these processes. First, the pro-
gressive accumulation of misfolded mutant SOD1 proteins may
trigger ER stress and UPR in SOD1A4V/þ motor neurons. In support
of this idea, SOD1A4V/þ motor neurons show a signiﬁcant increase
in the insoluble mutant SOD1 proteins when the neurons are
treated with proteasome inhibitor MG-132. Second, additional
evidence indicates that spinal cord motor neurons appear to have
inherently higher level of ER stress, which may be interconnected
with the unique electrophysiological properties endowed in motor
neurons. Interestingly, compared to control motor neurons,
SOD1A4V/þ motor neurons have reduced delayed-rectiﬁer po-
tassium current amplitudes, which may contribute to their hy-
perexcitability properties (Wainger et al., 2014). Remarkably, the
Kv7 channel activator retigabine blocks the hyperexcitability in
SOD1A4V/þ motor neurons and improves their survival in vitro.
These results support the idea that the hyperexcitable properties
of SOD1A4V/þ motor neurons may directly contribute to neurode-
generation in ALS. Intriguingly, similar up-regulation of ER stress-
related genes and hyperexcitability can also be detected in iPSC-
derived motor neurons that carry C9ORF72 or FUS mutations,
suggesting that protein misfolding and the ensuring consequences
of ER stress and UPR may have broader pathogenic roles in dif-
ferent subtypes of ALS (Wainger et al., 2014). Finally, one recent
study tests the utility of iPSC-derived motor neurons with SOD1
mutations in drug screening (Yang et al., 2013). The results from
this study show that blocking HGK (hepatocyte progenitor kinase
like or MAP4K4) with inhibitor kenpaullone can promote the
survival of SOD1L144F human iPSC-derived motor neurons as well
as mouse ESC-derived SOD1G93A motor neurons. These encoura-
ging results support the idea that iPSC-derived motor neurons can
be used as effective tools to identify novel therapeutic targets for
ALS.
2.2. Modeling C9ORF72 mutations
At least three mechanisms, including the formation of RNA foci,
repeat-associated non-ATG-initiated (RAN) translation products,
and loss-of-function in C9ORF72 gene product, have been postu-
lated to contribute to the neurodegeneration in C9ORF72 hex-
anucleotide repeat mutations (Gendron et al., 2014). Several
groups have generated iPSC-derived neurons and developed RNA
ﬂuorescent in situ hybridization (FISH) to show that 20–35% of
iPSC-derived neurons contain intranuclear GGGGCC RNA foci (Al-
meida et al., 2013; Donnelly et al., 2013; Sareen et al., 2013). The
presence of RNA foci in C9ORF72 iPSC-derived neurons re-
capitulates a key neuropathological feature of C9ORF72 mutations,
and further allows characterization of how the intranuclear RNA
foci might affect RNA metabolism. For instance, several RNA
binding proteins, including ADARB2, hnRNPA1, hnRNPA1B2, Pur-α,
FUS, and TDP-43, have been shown to potentially interact with
GGGGCC RNA repeats (Donnelly et al., 2013; Sareen et al., 2013).
However, so far only ADARB2 co-localizes with intranuclear RNA
foci, suggesting that such association might have functional con-
sequences (Donnelly et al., 2013). It is important to note that the
various C9ORF72 iPSC models have implicated different sets of RNA
binding proteins in the development of RNA foci. This variabilityth iPSC-derived neurons. Brain Research (2016), http://dx.doi.org/
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differences in the GGGGCC repeat lengths or other unknown fac-
tors (Table 1). Finally, despite the attention to RNA foci, it remains
unclear whether these foci are toxic to neurons or simply reﬂect
the disease state.
In addition to the intranuclear RNA foci, a higher percentage of
C9ORF72 iPSC-derived neurons contain cytoplasmic RNA foci,
suggesting that RAN translation may lead to accumulation of high
molecular weight cytoplasmic dipeptide protein products, in-
cluding poly-(Gly-Ala), poly-(Gly-Pro) and poly-(Gly-Arg) (Ash
et al., 2013; Mori et al., 2013). In support of this idea, im-
munohistochemical staining conﬁrms the presence of poly-(Gly-
Pro) dipeptide protein products in C9ORF72 iPSC-derived neurons
(Almeida et al., 2013; Donnelly et al., 2013). However, despite the
presence of RNA foci and RAN translation protein products in iPSC-
derived neurons, how these phenotypes directly contribute to
human disease remain unclear. For instance, the variations in the
quantity of RNA foci per cell in different lines of iPSC-derived
neurons suggest that the formation of RNA foci may not correlate
directly with the number of GGGGCC repeat, but perhaps may be
inﬂuenced by other genetic or epigenetic factors (Almeida et al.,
2013). Similarly, the levels of RAN translation protein products
appear to be independent of the GGGGCC repeat length. In at least
one study, the RAN translation protein products and aberrant in-
crease of proteasome marker p62 are not consistently detected
(Sareen et al., 2013). These results have also been further extended
by another recent study (Gomez-Deza et al., 2015), which shows a
distinct lack of RAN translation protein products in spinal motor
neurons in FALS patients with C9ORF72 mutations. In the future, it
will be important to use the iPSC models to determine how RAN
proteins induce p62 pathology and whether p62 pathology is
causally linked to neuronal degeneration and functional deﬁcits.
The C9ORF72 iPSC-derived neurons provide a convenient and
effective tool to further interrogate the pathogenesis of ALS. There
are several directions to achieve this goal. First, transcriptome
analyses in iPSC-derived motor neurons reveal misregulation of
genes that are involved in cell adhesion, synaptic transmission and
neural differentiation (Donnelly et al., 2013; Sareen et al., 2013).
Interestingly, however, direct comparison of the transcriptomes of
C9ORF72 iPSC-derived neurons and motor cortex of C9ORF72 ALS
patients shows very limited overlapping. This difference may be
due to the contribution of the glial cells in the motor cortex. Al-
ternatively, it is possible that the difference may reﬂect that the
iPSC-derived neurons represent a much earlier stage in the disease
manifestations. Second, C9ORF72 iPSC-derived neurons exhibit
elevated sensitivity to stress-mediated cytotoxicity. For instance,
C9ORF72 iPSC-derived neurons (mixed population with 30–40%
HB9þ neurons) exhibit more vulnerability to glutamate-mediated
cytotoxicity in a dose-dependent manner (Donnelly et al., 2013).
Similarly, another study indicated that C9ORF72 iPSC-derived
neurons show reduced viability when exposed to chloroquine, an
inhibitor that blocks the autophagy pathway (Almeida et al., 2013).
Finally, C9ORF72 iPSC-derived neurons should also provide a
convenient tool to investigate the potential loss-of-function effect
of C9ORF72 gene product in the regulation of endosomal traf-
ﬁcking and in the pathogenesis of TDP-43 proteinopathy, which
are common neuropathological features in these cases (Farg et al.,
2014; Gomez-Deza et al., 2015).
In addition to revealing disease mechanisms, C9ORF72 iPSC-
derived neurons provide an efﬁcient tool to identify potential
therapeutics. Based on the success of using antisense oligonu-
cleotides (ASOs) approach to reverse RNA toxicity due to myotonic
dystrophy (MD1) (Mulders et al., 2009), two studies showed that
ASOs that targets the GGGGCC repeat containing transcripts can
reduce RNA foci, normalize disease-speciﬁc transcriptional chan-
ges and rescue the increased vulnerability to glutamate toxicity,Please cite this article as: Lee, S., Huang, E.J., Modeling ALS and FTD wi
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et al., 2013; Sareen et al., 2013). These results conﬁrm that RNA
toxicity, rather than loss-of-function in C9ORF72, is likely to be the
major contributing factor to the pathogenesis of C9 ALS and pro-
vide a promising blueprint for future development of therapeutics.
2.3. Modeling TDP-43 mutations
The identiﬁcation of TDP-43 proteinopathy as a key neuro-
pathological feature in sporadic ALS and FTLD represents a major
advance in neurodegenerative disease research (Arai et al., 2006;
Neumann et al., 2006). Subsequent studies show that autosomal
dominant mutations in the TDP-43 gene TARDBP can indeed be
identiﬁed in both sporadic and familial ALS patients (Lagier-Tour-
enne and Cleveland, 2010), though the incidence of these muta-
tions is quite rare. To further understand how mutations in
TARDBP might alter the subcellular localization of TDP-43 pro-
teins, several groups have generated iPSC-derived motor neurons
that carry TDP-43 mutations, including TDP-43M337V, TDP-43Q343R,
TDP-43G298S, TDP-43A90V or TDP-43A315T. These iPSC lines provide
unique resources to determine whether these mutations directly
contribute to the pathogenesis of disease, or merely represent risk
factors. For instance, in control motor neurons wild type TDP-43
proteins are present predominantly in the soluble fraction. In
contrast, TDP-43M337V and TDP-43Q343R motor neurons show in-
creases of mutant TDP-43 proteins in the detergent-resistant in-
soluble fractions (Bilican et al., 2012; Egawa et al., 2012). These
results suggest that the increases in mutant TDP-43 proteins are
probably due to post-translational modiﬁcations rather than
transcriptional mechanisms. Although the exact cause(s) that
promote the accumulation of TDP-43 in the insoluble fractions
remain unclear, there is evidence that mutant TDP-43 can form
more stable complex with splicesome factor SNRPB2 (Egawa et al.,
2012), suggesting that mutant TDP-43 may disrupt the splicing
machinery through gain-of-function properties. Interestingly, au-
tomated live microscopy shows that TDP-43M337V motor neurons
have increased relative risks to undergo cell death. Together, these
results are in agreement with previously reported cellular and
transgenic TDP-43 models of elevated levels of cytoplasmic, but
not nuclear, TDP-43 correlates with cellular toxicity (Barmada
et al., 2010). The accumulation of cytoplasmic TDP-43 proteins in
TDP-43M337V motor neurons shows a signiﬁcant reduction when
these neurons are treated with allele-speciﬁc siRNA to knock-
down the mutant TDP-43M337V allele (Nishimura et al., 2014).
These results not only provide deﬁnitive evidence that the accu-
mulation of mutant TDP-43 proteins in cytoplasm is speciﬁc, they
also support the idea that RNA interference has the potential to
become an effective therapeutic tool for ALS.
Several studies further take advantage of the iPSC-derived
motor neurons to interrogate the roles of mutant TDP-43 in cell
autonomous and non-cell autonomous mechanisms that cause
motor neuron dysfunctions. For instance, TDP-43A90V and TDP-
43M337V iPSC-derived neurons exhibit increased vulnerability to
stress-induced cytotoxicity and reduced microRNA-9 expression
(Zhang et al., 2013). The ﬁndings in TDP-43A90V iPSCs are quite
intriguing because TDP-43A90V has been considered as a risk factor
for ALS. Hence, results from this study suggest that other addi-
tional factors, such as genetic background or environmental fac-
tors, may have contributed to the initiation and progression of
disease. With respect to TDP-43M337V mutation, gene expression
proﬁling in the puriﬁed TDP-43M337V iPSC-derived motor neurons
further reveals misregulation of genes that are implicated in RNA
metabolism and cytoskeleton functions (Egawa et al., 2012). In
particular, the expression of neuroﬁlament-medium (NEFM) and
neuroﬁlament-light (NEFL) chain is signiﬁcantly reduced in TDP-
43M337V iPSC-derived motor neurons. These results are similar toth iPSC-derived neurons. Brain Research (2016), http://dx.doi.org/
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suggesting that different genetic mutations may share the same
target genes leading to ALS phenotype. In another study that
combines three model systems, namely Drosophila motor neurons,
mouse cortical neurons and human iPSC-derived motor neurons,
Alami and colleagues provide compelling evidence that wild type
TDP-43 proteins form cytoplasmic mRNP granules and facilitate
the bidirectional, microtubule-dependent transport of these mRNP
granules in axons. In contrast, mutant TDP-43 proteins, either TDP-
43M337V or TDP-43A315T, consistently cause impairments in the
transport of NEFL (neuroﬁlament-L chain) mRNP granules in axons
(Alami et al., 2014). Given the pluripotent nature of iPSCs, these
cells provide rather convenient tools to determine whether glial
cells expressing mutant TDP-43 proteins might cause cytotoxicity
to motor neurons. Indeed, neural precursors from TDP-43M337V
iPSCs are treated with epidermal growth factor (EGF) and leuke-
mia inhibitory factor (LIF) for 4–6 weeks, followed by 14 days
treatment of ciliary neurotrophic factor (CNTF) to promote differ-
entiation to astrocytes. Using motor neuron-astrocyte co-cultures,
Serio and colleagues show that TDP-43M337V iPSC-derived astro-
cytes do not exhibit non-cell autonomous cytotoxic effects to
motor neurons (Serio et al., 2013).
Finally, TDP-43M337V iPSC-derived motor neurons also provide a
unique tool to identify potential therapeutic targets that may mi-
tigate the ALS phenotypes. To this end, Egawa and colleagues show
that when exposed to arsenite to induce oxidative stress, TDP-
43M337V iPSC-derived motor neurons show increase in insoluble
TDP-43 and reduced survival. This arsenite-induced motor neuron
death assay provides a convenient tool to identify anacardic acid
that can promote the survival of these neurons. Anacardic acid
reportedly reduces TDP-43 mRNA expression in TDP-43M337V iPSC-
derived motor neurons by 147-fold compared to untreated motor
neurons, and reduces the amount of insoluble TDP-43, but not
those in the soluble fractions. In addition, anacardic acid also in-
creases the neurite length, increases the expression of NEFM in
treated motor neurons, down-regulates the RNA metabolism-re-
lated genes, and reverses the changes in TNFα/NFκB signaling
pathway (Egawa et al., 2012).
2.4. Modeling sporadic ALS
Although TDP-43 proteinopathy is a common feature in
sporadic ALS, the cause-effect relationship between TDP-43 pro-
tein aggregates and the pathogenesis of ALS remains unclear. This
is complicated by the observations that mutations in TDP-43 gene
TARDBP are quite rare in sporadic ALS cases, and that TDP-43
proteinopathy can also be identiﬁed in other neurodegenerative
diseases, such as Alzheimer's disease (Amador-Ortiz et al., 2007).
Moreover, none of the rodent models that express wild type or
mutant TDP-43 show deﬁnitive TDP-43 proteinopathy that re-
capitulates human pathology. Given these limitations, the iPSC-
derived motor neurons provide an ideal and highly relevant model
to address this important question. Currently, only one study re-
ports the isolation and characterization of iPSC-derived motor
neurons from sporadic ALS cases. While the results require further
veriﬁcations, this study shows that under basal culture conditions,
motor neurons in sporadic ALS patients inherently have a higher
propensity to develop intranuclear TDP-43 aggregates even with-
out the presence of stress (Burkhardt et al., 2013). Although these
ﬁndings are encouraging, these inclusions only capture one feature
of TDP-43 proteinopathy in sporadic ALS. There is no evidence that
TDP-43 aggregates are identiﬁed in the cytoplasm or neuronal
processes in sporadic ALS iPSC-derived motor neurons. It is also
unclear if these intranuclear TDP-43 aggregates are ubiquitinated
or hyperphosphorylated just like those identiﬁed in human tis-
sues. Using intranuclear TDP-43 aggregates as readouts, this studyPlease cite this article as: Lee, S., Huang, E.J., Modeling ALS and FTD wi
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the formation of TDP-43 protein aggregates.
2.5. Modeling progranulin mutations
Autosomal dominant mutations in human progranulin (GRN)
gene have been causally linked to FTD. Although it is well-estab-
lished that non-sense-mediated decay of mutant progranulin
mRNA contributes to haploinsufﬁciency, the exact mechanisms of
neurodegeneration caused by PGRN deﬁciency are not entirely
clear. Patient-speciﬁc iPSC-derived neurons that carry GRNS116X
mutation show about 50% loss of PGRN mRNA, as well as secreted
and intracellular PGRN proteins. GRNS116X iPSC-derived neurons
exhibit increased sensitivity to a number of cellular stress condi-
tions, including treatment with ER stress inducer tunicamycin and
inhibitors for PI3 kinase (PI3K), AKT, and ERK/MAPK signaling
pathways (Almeida et al., 2012). Interestingly, lentivirus-mediated
expression of PGRN in GRNS116X iPSC-derived neurons rescues the
elevated sensitivity to cellular stress conditions. In addition, gene
expression proﬁling show that GrnS116X iPSC-derived neurons have
reduced expression of ribosomal protein S6 kinase beta-2
(RPS6KB2), a member of the S6 kinase family that has been im-
plicated in both PI3K/AKT and MEK/MAPK signaling pathways
(Fenton and Gout, 2011).
Although GRNS116X iPSC-derived neurons have no problem with
neuronal differentiation, iPSCs derived from another mutation
GRNIVS1þ5G4C show reduced differentiation efﬁciency into CTIP2-,
FOXP2- or TBR1-positive cortical neurons (Raitano et al., 2015).
This defect can be corrected by zinc ﬁnger nuclease-mediated
rescue of GRN cDNA. Interestingly, transcriptome analyses in
GRNIVS1þ5G4C iPSC-derived cortical neurons reveal that genes in
the Wnt signaling pathway are signiﬁcantly misregulated (Rosen
et al., 2011), and treatment of GRNIVS1þ5G4C iPSCs with Wnt in-
hibitors can restore the neuronal differentiation phenotype.
2.6. Modeling MAPT mutations
Mutations in human MAPT gene are a major contributing factor
to the pathogenesis of familial FTD (Wolfe, 2009). The neuro-
pathology features in these patients are characterized by the
profound tau protein aggregates in the cytoplasm and processes of
neurons and glia (frontotemporal lobar degeneration-tau or FTLD-
tau). The large number of tau protein isoforms, alternatively
spliced products, and various post-translational modiﬁcations
make it quite challenging to decipher the mechanisms of tau
protein aggregate formation and its contribution to disease pro-
cess. The majority of MAPT mutations are missense mutations that
cluster around the microtubule binding domain, suggesting that
these mutations most likely perturb the ability of tau to bind to
microtubules and cause neuronal dysfunction or even death.
Several groups have reported the isolation of iPSC-derived neu-
rons, including one with MAPTA152T mutation from a patient with
progressive supranuclear palsy (PSP), one with MAPTN279K and
MAPTV337M from FTDP-17 patients, and one with 10þ16 splice site
mutation in MAPT gene (Ehrlich et al., 2015; Fong et al., 2013;
Sposito et al., 2015). The study by Fong et al. (2013) showed that
MAPTA152T neurons exhibit distinct degenerative features, char-
acterized by breaks, bends and bulges along neuronal processes
and reduced neuronal survival. Interestingly, MAPTA152T iPSC-de-
rived neurons show phosphorylated tau protein aggregates in
cytoplasm and neuronal processes, though no abnormal tau pro-
tein aggregates are identiﬁed in astrocytes derived fromMAPTA152T
iPSCs. Using zinc ﬁnger nuclease-mediated gene editing, the au-
thors showed that the phenotypes in MAPTA152T iPSC-derived
neurons can be further aggravated when the mutation is present
in both allele (MAPT152T/T). Conversely, genetic correction of theth iPSC-derived neurons. Brain Research (2016), http://dx.doi.org/
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phenotypes in isogenic iPSC-derived neurons. Furthermore,
MAPT152A/T and MAPT152T/T iPSC-derived neurons show very low
percentage of dopaminergic neurons, which can be reversed by
genetic correction. Together, these results suggest that the dopa-
minergic neurons may be more vulnerable to neurotoxicity caused
byMAPTA152T mutation. These interesting ﬁndings support the idea
that MAPTA152T is a disease risk factor that affects the development
and maintenance of neuronal processes.
The effects of MAPT mutations in the development of neuronal
processes are further conﬁrmed in neurite outgrowth assays using
iPSC-derived neurons with MAPTN279K or MAPTV337M mutation
(Ehrlich et al., 2015). In addition, iPSC-derived neurons with
MAPTN279K or MAPTV337M mutation are much more vulnerable to
oxidative stress-induced toxicity, which is supported by an in-
crease in unfolded protein response (UPR) and distinct “disease-
speciﬁc” gene expression proﬁles. Finally, it is well-recognized that
different isoforms of tau can be generated via alternative splicing.
Using iPSCs from controls and two patients with 10þ16 splice-site
mutation in MAPT, Sposito and colleagues show that control iPSC-
derived neurons express 3R tau only during the ﬁrst 100 days in
culture (Sposito et al., 2015). Interestingly, prolonged culturing of
control neurons switches the tau expression from 3R tau to a di-
verse complement of tau isoforms. In contrast, iPSC-derived neu-
rons with 10þ16 splice site mutation inMAPT express both 3R and
4R tau during the ﬁrst 100 days in culture. These results suggest
that FTD-related splice site mutation in MAPT can override the
developmental program that determines splicing-mediated gen-
eration of tau isoforms. Given the robust post-translational mod-
iﬁcations of tau, it will be useful to take advantage of patient-
speciﬁc iPSCs to investigate the signaling mechanisms that reg-
ulate phosphorylation and acetylation of tau, and how perturba-
tions to these mechanisms contribute to disease.3. Concluding remarks and future directions
3.1. Conclusions and potential caveats
The large numbers of studies using iPSCs derived from ALS and
FTD patients have led to several important conclusions. First, it is
highly feasible to generate patient-speciﬁc iPSCs and harness the
genetic editing technology to correct mutations. Second, most
iPSC-derived neurons that carry disease-causing mutations can
recapitulate certain key features of human disease, including
proteinopathy and RNA toxicity. Third, the phenotypes observed in
iPSC-derived neurons provide conﬁdence that they can be quite
effective models for ALS and FTD. Finally, these studies also sup-
port the feasibility of using iPSC-derived neurons as platforms for
the discovery of disease-speciﬁc therapeutic targets.
Despite these promising results, however, there are several
caveats that deserve our attention before entering the next phase
of research using iPSC-derived neurons. For example, there is
sufﬁcient evidence that phenotypic variations do exist in iPSC-
derived neurons. In the case of C9ORF72 mutations, at least two
studies have reported distinct differences in the electro-
physiological properties in iPSC-derived neurons (Devlin et al.,
2015; Sareen et al., 2013). Despite using the same reagents to
characterize C9ORF72 iPSC-derived neurons, not all the studies are
able to identify RAN translation protein products (Sareen et al.,
2013). Furthermore, although all disease-speciﬁc iPSC-derived
neurons exhibit increased vulnerability to stress conditions, it is
unclear if these phenotypes are disease-speciﬁc, nor do we know
the underlying mechanisms that contribute to these phenotypes.
Looking ahead, as we improve and reﬁne iPSC-derived neurons as
bona ﬁde disease models, it will be important to compare andPlease cite this article as: Lee, S., Huang, E.J., Modeling ALS and FTD wi
10.1016/j.brainres.2015.10.003icontrast the similarities and differences with human neuro-
pathological features. Furthermore, by expanding the repertoire of
neuron subtypes from iPSCs, we can begin to determine the mo-
lecular mechanisms that deﬁne “selective vulnerability” that is a
consistent feature in neurodegenerative disease.
3.2. Future directions
The diverse phenotypes reported in iPSC-derived neurons that
carry pathogenic mutations causally linked to ALS or FTD pose
challenges for future efforts to identify therapeutic targets. While
the ASO-mediated knock down of RNA foci caused by C9ORF72
GGGGCC expansions provide promising therapeutic strategies, it
could be a daunting task to restore the hundreds, or thousands, of
disrupted RNA processing events that may occur following se-
questration of RNA processing factors by repeat expansion RNAs.
For example, many proteins involved in RNA metabolism, RNA
transport and splicing have been isolated in the interactomes of
GGGGCC RNA repeats, but it remains unclear whether ASO-based
therapeutic approaches will be sufﬁcient to mitigate the gain-of-
function properties of RNA repeats (Lagier-Tourenne et al., 2013;
Wheeler et al., 2012). Another challenge for ASO-based approach is
to develop highly efﬁcient delivery of ASO into brain and spinal
cord. Considering these obstacles, small molecule inhibitors that
aim at disrupting speciﬁc RNA-protein interactions might cir-
cumvent the technical challenges confronting ASO-based therapy
and be more effective in releasing endogenous proteins from the
gain-of-function properties of RNA repeats (Arambula et al., 2009;
Jahromi et al., 2013; Warf et al., 2009). In this context, C9ORF72
iPSC-derived neurons should serve as effective tools to screen for
small molecule inhibitors. Given the variations and diversity in
human disease, it might be more prudent to develop patient-
speciﬁc iPSC-derived neurons for the purpose of screening for the
best and most effective ASO and small molecule candidates.
Another therapeutic potential is to use iPSC-derived neurons in
cell-based therapy to replace disease-damaged neurons and to
restore the normal function of speciﬁc neural circuits. Several
studies in rodents and in chicks have provided proof-of-principle
evidence that iPSC-derived neurons can indeed be transplanted
into cerebral cortex or spinal cord, and demonstrate functional
integration into the existing neural circuits (Espuny-Camacho
et al., 2013; Sareen et al., 2014; Toma et al., 2015). Given the
available technology to correct the genetic mutations, it is possible
that patient-speciﬁc iPSC-derived neurons might be able to reduce
immune response and improve the chance of graft survival.Acknowledgments
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